Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer

Ben Zhang,Lixi Zhang,Peng Qi,Renzhu Pang,Ziming Wang,Xuyao Liu,Qi Shi,Qiang Zhang
DOI: https://doi.org/10.1038/s41598-023-32733-y
IF: 4.6
2023-04-10
Scientific Reports
Abstract:Abstract Papillary carcinomas account for the largest proportion of thyroid cancers, with papillary thyroid carcinoma (PTC) being prone to early lymph node metastasis. Some studies have confirmed that LPAR5 can promote the progression of PTC, but immune-related analyses of LPAR5 and PTC have not been widely discussed. This study aimed to determine the role of LPAR5 in PTC prognosis and immunity. We will further explore the role of LPAR5 in 33 different tumor types. Regarding PTC, we analyzed the effect of LPAR5 expression on overall survival (OS). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Immune-related analyses of immune checkpoints (ICPs) and immune cell infiltration were also performed. For pan-cancer, R packages were used to analyze prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), and immune cell infiltration. Analysis of tumor microenvironment (TME) and ICPs was performed using Sangerbox ( http://vip.sangerbox.com/home.html ). The TISIDB database ( http://cis.hku.hk/TISIDB/index.php ) was used to identify immune and molecular subtypes. LPAR5 expression is associated with PTC prognosis and immunity as well as various human tumors. LPAR5 may be a potential biomarker for multiple malignancies and may provide a new target for cancer immunotherapy.
multidisciplinary sciences
What problem does this paper attempt to address?
The main issue this paper attempts to address is the exploration of the prognostic value and immune function of the LPAR5 gene in papillary thyroid carcinoma (PTC) and pan-cancer. Specifically: 1. **Research in PTC**: - Analyzed the expression differences of the LPAR5 gene in PTC tissues and normal thyroid tissues. - Investigated the relationship between LPAR5 gene expression levels and clinicopathological features of PTC patients (such as T stage, N stage, tumor stage, etc.). - Evaluated the impact of LPAR5 gene expression on the overall survival (OS) of PTC patients. - Conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to reveal the functions and signaling pathways of the LPAR5 gene. - Studied the relationship between the LPAR5 gene and immune checkpoints (ICPs) and immune cell infiltration. 2. **Pan-cancer research**: - Analyzed the expression of the LPAR5 gene in 33 different cancer types. - Investigated the relationship between LPAR5 gene expression and tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, etc. - Evaluated the prognostic value of the LPAR5 gene in different cancer types (including overall survival, disease-free survival, disease-specific survival, and progression-free survival). - Studied the relationship between LPAR5 gene expression and immune subtypes and molecular subtypes. Through these studies, the paper aims to better understand the role of the LPAR5 gene in anti-tumor immunotherapy and provide scientific evidence for its potential as a biomarker and new target for immunotherapy in various malignancies.